Suppr超能文献

受控物质处方模式 - 处方行为监测系统,八个州,2013 年。

Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.

机构信息

Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC.

出版信息

MMWR Surveill Summ. 2015 Oct 16;64(9):1-14. doi: 10.15585/mmwr.ss6409a1.

Abstract

PROBLEM/CONDITION: Drug overdose is the leading cause of injury death in the United States. The death rate from drug overdose in the United States more than doubled during 1999-2013, from 6.0 per 100,000 population in 1999 to 13.8 in 2013. The increase in drug overdoses is attributable primarily to the misuse and abuse of prescription drugs, especially opioid analgesics, sedatives/tranquilizers, and stimulants. Such drugs are prescribed widely in the United States, with substantial variation by state. Certain patients obtain drugs for nonmedical use or resale by obtaining overlapping prescriptions from multiple prescribers. The risk for overdose is directly associated with the use of multiple prescribers and daily dosages of >100 morphine milligram equivalents (MMEs) per day.

PERIOD COVERED

DESCRIPTION OF SYSTEM

The Prescription Behavior Surveillance System (PBSS) is a public health surveillance system that allows public health authorities to characterize and quantify the use and misuse of prescribed controlled substances. PBSS began collecting data in 2012 and is funded by CDC and the Food and Drug Administration. PBSS uses standard metrics to measure prescribing rates per 1,000 state residents by demographic variables, drug type, daily dose, and source of payment. Data from the system can be used to calculate rates of misuse by certain behavioral measures such as use of multiple prescribers and pharmacies within specified time periods. This report is based on 2013 de-identified data (most recent available) that represent approximately one fourth of the U.S.

POPULATION

Data were submitted quarterly by prescription drug monitoring programs (PDMPs) in eight states (California, Delaware, Florida, Idaho, Louisiana, Maine, Ohio, and West Virginia) that routinely collect data on every prescription for a controlled substance to help law enforcement and health care providers identify misuse or abuse of such drugs.

RESULTS

In all eight states, opioid analgesics were prescribed approximately twice as often as stimulants or benzodiazepines. Prescribing rates by drug class varied widely by state: twofold for opioids, fourfold for stimulants, almost twofold for benzodiazepines, and eightfold for carisoprodol, a muscle relaxant. Rates for opioids and benzodiazepines were substantially higher for females than for males in all states. In most states, opioid prescribing rates peaked in either the 45-54 years or the 55-64 years age group. Benzodiazepine prescribing rates increased with age. Louisiana ranked first in opioid prescribing, and Delaware and Maine had relatively high rates of use of long-acting (LA) or extended-release (ER) opioids. Delaware and Maine ranked highest in both mean daily opioid dosage and in the percentage of opioid prescriptions written for >100 MMEs per day. The top 1% of prescribers wrote one in four opioid prescriptions in Delaware, compared with one in eight in Maine. For the five states whose PDMPs collected the method of payment, the percentage of controlled substance prescriptions paid for in cash varied almost threefold, and the percentage paid by Medicaid varied sixfold. In West Virginia, for 1 of every 5 days of treatment with an opioid, the patient also was taking a benzodiazepine. Multiple-provider episode rates were highest in Ohio and lowest in Louisiana.

INTERPRETATION

This report presents rates of population-based prescribing and behavioral measures of drug misuse in the general population that have not been available previously for comparison among demographic groups and states. The higher prescribing rates for opioids among women compared with men are consistent with a higher self-reported prevalence of certain common types of pain, such as lower back pain among women. The trend in opioid prescribing rates with age is consistent with an increase in the prevalence of chronic pain with age, but the increasing prescribing rates of benzodiazepines with age is not consistent with the fact that anxiety is most common among persons aged 30-44 years. The variation among states in the type of opioid or benzodiazepine of choice is unexplained. Most opioid prescribing occurs among a small minority of prescribers. Most of the prescriptions by top-decile prescribers probably are written by general, family medicine, internal medicine, and midlevel practitioners. The source of payment varied by state, for reasons that are unclear. Persons who are prescribed opioids also are commonly prescribed benzodiazepine sedatives despite the risk for additive depressant effects.

PUBLIC HEALTH ACTIONS

States can use their prescription drug monitoring programs to generate population-based measures for the prescribing of controlled substances and for behaviors that suggest their misuse. Comparing data with other states and tracking changes in these measures over time can be useful in measuring the effect of policies designed to reduce prescription drug misuse.

摘要

问题/状况:在美国,药物过量是导致伤害死亡的主要原因。自 1999 年至 2013 年,美国药物过量死亡率增加了一倍以上,从 1999 年的每 10 万人中有 6.0 例增加到 2013 年的 13.8 例。药物过量的增加主要归因于处方药物的滥用和误用,尤其是阿片类镇痛药、镇静剂/安定剂和兴奋剂。这些药物在美国广泛使用,各州之间存在很大差异。某些患者通过从多个开处方者那里获得重叠处方来获取药物供非医疗用途或转售。过量用药的风险与使用多个开处方者和每日剂量超过 100 吗啡毫克当量(MME)直接相关。

涵盖时期

2013 年。

系统描述

处方行为监测系统(PBSS)是一种公共卫生监测系统,允许公共卫生当局对规定的受控物质的使用和滥用进行特征描述和量化。PBSS 于 2012 年开始收集数据,由疾病预防控制中心和美国食品和药物管理局共同资助。PBSS 使用标准指标来衡量按人口统计学变量、药物类型、每日剂量和付款来源计算的每千名州居民的开处方率。该系统的数据可用于通过某些行为措施(如在特定时间段内使用多个开处方者和药房)计算滥用率。本报告基于 2013 年(最新)的匿名数据,这些数据代表了美国的四分之一左右。

人口

八个州(加利福尼亚州、特拉华州、佛罗里达州、爱达荷州、路易斯安那州、缅因州、俄亥俄州和西弗吉尼亚州)的处方药监测计划(PDMP)每季度提交数据,这些州常规收集有关每种受控物质处方的信息,以帮助执法部门和医疗保健提供者识别此类药物的滥用或误用。

结果

在所有八个州,阿片类镇痛药的处方频率大约是兴奋剂或苯二氮卓类药物的两倍。按药物类别划分的开处方率因州而异:阿片类药物的处方频率为两倍,兴奋剂的处方频率为四倍,苯二氮卓类药物的处方频率几乎为两倍,肌肉松弛剂卡马西平的处方频率为八倍。在所有州,女性的阿片类药物和苯二氮卓类药物的处方频率均显著高于男性。在大多数州,阿片类药物的处方频率在 45-54 岁或 55-64 岁年龄组达到峰值。苯二氮卓类药物的处方频率随年龄增长而增加。路易斯安那州的阿片类药物处方率最高,而特拉华州和缅因州的长效(LA)或缓释(ER)阿片类药物的使用率相对较高。在每日阿片类药物剂量和每天开 100 MME 以上处方的百分比方面,缅因州和特拉华州的排名最高。在这五个州中,其 PDMP 收集支付方式的方法,受管制物质处方中现金支付的百分比相差近三倍,而医疗补助支付的百分比相差六倍。在西弗吉尼亚州,每五分之一接受阿片类药物治疗的患者同时还在服用苯二氮卓类药物。俄亥俄州的多处方者发生比例最高,而路易斯安那州的比例最低。

解释

本报告介绍了人口为基础的开处方率和药物滥用的行为措施,这些数据在以前的比较中没有在人口群体和各州之间进行比较。与男性相比,女性的阿片类药物处方率较高,这与女性更常见某些常见类型的疼痛(如腰痛)的自我报告患病率较高一致。阿片类药物处方率随年龄增长的趋势与慢性疼痛随年龄增长的患病率增加一致,但随着年龄增长,苯二氮卓类药物的处方率增加与焦虑症最常见于 30-44 岁人群的事实不一致。选择阿片类药物或苯二氮卓类药物的类型在各州之间的差异无法解释。大多数阿片类药物处方由一小部分开处方者开具。大多数顶级开处方者的处方可能由普通医生、家庭医生、内科医生和中级从业者开具。付款来源因州而异,原因尚不清楚。开阿片类药物处方的患者也经常开苯二氮卓类镇静剂处方,尽管存在累加镇静作用的风险。

公共卫生行动

各州可以使用其处方药监测计划生成人口为基础的受管制物质开处方率和行为措施,这些措施表明药物滥用。将数据与其他州进行比较,并跟踪这些措施随时间的变化,可以有助于衡量旨在减少处方药物滥用的政策的效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验